APVO - アプテボ・セラピュ―ティクス (Aptevo Therapeutics Inc.) アプテボ・セラピュ―ティクス

 APVOのチャート


 APVOの企業情報

symbol APVO
会社名 Aptevo Therapeutics Inc (アプテボ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アプテボ・セラピューティクス(Aptevo Therapeutics Inc.)はバイオ技術会社である。同社は患者の生命を管理するためにオンコロジー(がん)及び血液学(血液疾患)治療薬の生産に従事する。同社の事業はオンコロジー及び血液学治療薬の発見・開発・商品化・販売を行う。核心技術はADAPTIS(モジュラータンパク質技術)プラットフォームである。同社は血液学と感染症分野で約4つの製品を有し、並びに免疫腫瘍学における多様な治験段階の製品候補を有する。その治験段階の製品候補であるMOR209/ES414、ES210、ES425及びotlertuzumabはADAPTISプラットフォーム上に構築される。同社の販売製品は「WinRho SDF」(抗 D(Rho)ヒト免疫グロブリン)、「HepaGam B」(B型肝炎ヒト免疫グロブリン)、「VARIZIG」(水痘帯状疱疹ヒト免疫グロブリン)及び「IXINITY」(血液凝固第IX因子(組換え型))である。   アプテボ・セラピュ―ティクスは米国のバイオ医薬品企業。主にがんと血液疾患に対し、同社開発のモジュラ―・タンパク質技術「ADAPTIR」による治療に従事する。がん治療、免疫療法に利用される候補薬に「MOR209/ES414」、「ES210」、「ES425」、「Otlertuzumab」などを含む。本社はワシントン州シアトル。   Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed based on the Company's versatile and robust ADAPTIR™ modular protein technology platform. The ADAPTIR™ platform is capable of generating highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer.
本社所在地 2401 4th Avenue Suite 1050 Seattle WA 98121 USA
代表者氏名
代表者役職名
電話番号 +1 206-838-0500
設立年月日 42401
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 121人
url www.AptevoTherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/apvo
adr_tso
EBITDA EBITDA(百万ドル) -50.97500
終値(lastsale) 4.6
時価総額(marketcap) 104279263
時価総額 時価総額(百万ドル) 102.46570
売上高 売上高(百万ドル) 19.88700
企業価値(EV) 企業価値(EV)(百万ドル) 77.30170
当期純利益 当期純利益(百万ドル) -33.79400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aptevo Therapeutics Inc revenues increased 92% to $10.9M. Net loss before extraordinary items increased 5% to $27.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 52% to $17.4M (expense) Other expense from continuing operations increase of 22% to $1.1M (expense).

 APVOのテクニカル分析


 APVOのニュース

   Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index - Stocks News Feed  2021/06/29 12:38:41 Stocks News Feed
SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. (Aptevo) (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies today announced that the company has been added to the Russell Microcap® Index at the conclusion of the 2021 annual reconstitution. Aptevos Read More »Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
   Aptevo Therapeutics added to the Russell Microcap Index  2021/06/29 12:32:59 Seeking Alpha
   Aptevo Therapeutics Announces Inclusion in the Russell Microcap Index  2021/06/29 12:08:00 FinanzNachrichten
SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based o
   Aptevo CEO says Seattle biotech scene is ''robust and growing''  2021/06/26 03:00:00 Business Journals
Aptevo Therapeutics is a small, passion-driven biotech company that, I am proud to say, lives its principles, CEO Marvin White said. Its our biggest strength and motivates us as individuals and as a team.
   Aptevo Therapeutics Insights: Return On Capital Employed  2021/06/18 14:22:21 Benzinga
In Q1, Aptevo Therapeutics (NASDAQ: APVO ) posted sales of $2.42 million. Earnings were up 1.01%, but Aptevo Therapeutics still reported an overall loss of $6.89 million. In Q4, Aptevo Therapeutics brought in $2.37 million in sales but lost $6.82 million in earnings. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful Full story available on Benzinga.com
   Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial  2021/01/11 13:00:00 Yahoo Finance
SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today provided an update on its ongoing APVO436 phase 1 clinical trial.
   Global Bi Syndrome Treatment Market 2020:Quantitative Analysis By Aptevo THERAPEUTICS INC., OncoMed Pharmaceuticals, Inc., Roche, MacroGenics, Inc., AbbVie Inc., Regeneron Pharmaceuticals, Inc., Xencor  2020/11/20 13:21:04 OpenPR
This Bi Syndrome Treatment report provides complete analysis of the market on global and regional level. It inspects the development rate and the market value dependent on the market elements and growth initiating factors. The market players
   APVO Gets Buyout Offer, PFE/BNTX' COVID Shot 95% Effective, CORT Gets Favorable PTAB Ruling  2020/11/19 02:13:00 RTT News
Today's Daily Dose brings you news about the buyout offer received by Aptevo, updated efficacy data of Pfizer/BioNTech's COVID-19 vaccine candidate, Corcept receiving a favorable ruling from Patent Trial & Appeal Board related to the U.
   80 Biggest Movers From Yesterday  2020/11/11 10:01:48 Benzinga
Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC ) shares surged 120.5% to close at $5.16 on Tuesday after the company reported it will begin offering integrated electric drivetrain system to existing forklift OEM clientele to support manufacture of electric forklifts using lithium batteries. Summit Wireless Technologies, Inc. (NASDAQ: WISA ) rose 70.4% to close at $3.63 after the company reported 45% year-over-year revenue growth for the third quarter. The company also said it sees more than 100% year-over-year revenue growth for Q4. Revlon, Inc. (NYSE: REV ) gained 47.2% to close at $8.79. Trxade Group, Inc. (NASDAQ: MEDS ) shares rose 41.9% to close at $6.10 after the company entered into a solution marketing program agreement with Amazon.com Services, LLC to promote Amazon storage lockers. Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) climbed 35.4% to close at $11.51 after the company posted a profit for the third quarter. Aptevo Therapeutics Inc. (NASDAQ: APVO ) gained 35.4% to close at $44.32.
   Aptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update - Stocks News Feed  2020/11/10 22:39:57 Stocks News Feed
$1.5 million of RUXIENCE® Royalties Earned in the Third Quarter Funding Extends Cash Runway Into Q3 2021 SEATTLE, WA / ACCESSWIRE / November 10, 2020 / Aptevo Therapeutics Inc. (“Aptevo” or “the Company”) (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today reported financial results… Read More »Aptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update
   Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial  2021/01/11 13:00:00 Yahoo Finance
SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today provided an update on its ongoing APVO436 phase 1 clinical trial.
   Global Bi Syndrome Treatment Market 2020:Quantitative Analysis By Aptevo THERAPEUTICS INC., OncoMed Pharmaceuticals, Inc., Roche, MacroGenics, Inc., AbbVie Inc., Regeneron Pharmaceuticals, Inc., Xencor  2020/11/20 13:21:04 OpenPR
This Bi Syndrome Treatment report provides complete analysis of the market on global and regional level. It inspects the development rate and the market value dependent on the market elements and growth initiating factors. The market players
   APVO Gets Buyout Offer, PFE/BNTX' COVID Shot 95% Effective, CORT Gets Favorable PTAB Ruling  2020/11/19 02:13:00 RTT News
Today's Daily Dose brings you news about the buyout offer received by Aptevo, updated efficacy data of Pfizer/BioNTech's COVID-19 vaccine candidate, Corcept receiving a favorable ruling from Patent Trial & Appeal Board related to the U.
   80 Biggest Movers From Yesterday  2020/11/11 10:01:48 Benzinga
Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC ) shares surged 120.5% to close at $5.16 on Tuesday after the company reported it will begin offering integrated electric drivetrain system to existing forklift OEM clientele to support manufacture of electric forklifts using lithium batteries. Summit Wireless Technologies, Inc. (NASDAQ: WISA ) rose 70.4% to close at $3.63 after the company reported 45% year-over-year revenue growth for the third quarter. The company also said it sees more than 100% year-over-year revenue growth for Q4. Revlon, Inc. (NYSE: REV ) gained 47.2% to close at $8.79. Trxade Group, Inc. (NASDAQ: MEDS ) shares rose 41.9% to close at $6.10 after the company entered into a solution marketing program agreement with Amazon.com Services, LLC to promote Amazon storage lockers. Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) climbed 35.4% to close at $11.51 after the company posted a profit for the third quarter. Aptevo Therapeutics Inc. (NASDAQ: APVO ) gained 35.4% to close at $44.32.
   Aptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update - Stocks News Feed  2020/11/10 22:39:57 Stocks News Feed
$1.5 million of RUXIENCE® Royalties Earned in the Third Quarter Funding Extends Cash Runway Into Q3 2021 SEATTLE, WA / ACCESSWIRE / November 10, 2020 / Aptevo Therapeutics Inc. (“Aptevo” or “the Company”) (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today reported financial results… Read More »Aptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アプテボ・セラピュ―ティクス APVO Aptevo Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)